Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Recent research evidence is now emerging in support of its therapeutic potential for different pathologies including neurodegenerative diseases.Herein, the <i>C. sativus</i> L. natural compounds <i>trans</i>-crocin 4 and <i>trans</i>-crocetin were selected for in depth molecular characterization of their potentially protective effects against Alzheimer's Disease (AD), utilizing two AD neuronal cell culture models (SH-SY5Y overexpressing APP and PC12 expressing hyperphosphorylated tau).
|
30971876 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Efficient inhibitors are highly desired for the prevention of Aβ assembly that has been considered as the primary therapeutic strategy for neurodegenerative diseases.
|
31148450 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alzheimer's disease (AD) is a slowly progressing neurodegenerative disorder that attributed to the increase of amyloid precursor protein (APP).
|
30951743 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We demonstrate that HARDEN can be applied to the neurodegenerative disease genes C9orf72 and APP, and methylation can be induced via HDR with both single and double stranded methylated repair templates.
|
31680172 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In doing so, we aim to invigorate research and discussion around non-amyloidogenic APP processing products and the mechanisms linking mitochondria and complex neurodegenerative disorders such as sporadic Alzheimer's disease.
|
30471088 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alzheimer's is a complex neurodegenerative disease and is characterized by extraneuronal accumulation of β-amyloid peptide.
|
31655280 |
2019 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
APP is involved in the pathology of Alzheimer's disease (AD), the most common neurodegenerative disorder causing dementia.
|
29383688 |
2018 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alzheimer disease (AD) is a common neurodegenerative disease that is characterized by the deposition of beta-amyloid peptide and formation of intracellular neurofibrillary tangles.
|
29587274 |
2018 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We discuss the specific interactions with APP, the capacity to modulate the intracellular itinerary and the proteolytic conversion of APP, a possible involvement in the clearance of Aβ, and the implications of these transmembrane proteins in AD and other neurodegenerative diseases.
|
29079999 |
2018 |
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Alzheimer's disease (AD) is a neurodegenerative disease driven in large part by accumulated deposits in the brain of the amyloid precursor protein (APP) cleavage product amyloid-β peptide (Aβ).
|
29426354 |
2018 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Reduction in amyloid beta deposition by activation of p-AMPK influencing APP processing genes makes osmotin a potent therapeutic candidate for neurodegenerative diseases.
|
28811634 |
2017 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, APP might serve as a common therapeutic target against Alzheimer's Disease (AD) and a host of other neurodegenerative diseases characterized by abnormal levels of Aβ and/or Tau.
|
28696204 |
2017 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alzheimer's disease is an age-related neurodegenerative disorder characterized by a progressive decline in cognitive function due to the extracellular accumulation and deposition of beta-amyloid peptide (Aβ).
|
28411131 |
2017 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The lipid raft microenvironment is implicated in the generation of the pathological amyloid-β (Aβ) species in amyloid precursor protein (APP) that is associated with neurodegenerative diseases.
|
28562045 |
2017 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The method is useful for identifying the defective APP-mRNA isoform in LND patients, and in neurodevelopmental and neurodegenerative disorders in which the APP gene is involved in the pathogenesis of diseases such as autism, fragile X syndrome, amyotrophic lateral sclerosis, and Alzheimer's disease, and may pave the way for new strategies applicable to rational antisense drugs design.
|
28192196 |
2017 |
Neurodegenerative Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Therefore, inhibition of the IRE-modulated expression of APP and α-Syn or chelation of iron in patient's brains has therapeutic significance to human neurodegenerative diseases.
|
29061112 |
2017 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Its neuroprotective effects are mediated, in part, by regulation of APP processing and Aβ degradation, and thus, ALA might be a potential candidate for prevention or treatment of neurodegenerative diseases such as AD.
|
29092397 |
2017 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The biological fates of the key initiator of Alzheimer's disease (AD), the amyloid precursor protein (APP), and a family of lipoprotein receptors, the low-density lipoprotein (LDL) receptor-related proteins (LRPs) and their molecular roles in the neurodegenerative disease process are inseparably interwoven.
|
28298885 |
2017 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Alzheimer's disease (AD) is a neurodegenerative disorder known for the presence of amyloid beta plaques resulting from the sequential action of β-secretase and γ-secretase on amyloid precursor protein.
|
29107423 |
2017 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Disordered APP metabolism and neurovasculature in trauma and aging: Combined risks for chronic neurodegenerative disorders.
|
27829172 |
2017 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Overall, our results suggest strongly that US9 can serve as a molecular driver that targets functional cargos to the APP machinery and can be used as a tool to study the contribution of lipid rafts to neurodegenerative disease conditions where amyloidogenesis has been implicated.
|
29118375 |
2017 |
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Alzheimer's disease (AD), a major neurodegenerative disorder, is associated with the enzymatic reaction of β-secretase (BACE1) on the amyloid precursor protein (APP) for the generation of neurotoxic amyloid-β (Aβ).
|
27511641 |
2016 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Mutations in genes encoding subunits of the m-AAA protease have been linked to various neurodegenerative diseases in humans, such as hereditary spastic paraplegia and spinocerebellar ataxia.
|
27911893 |
2016 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our observations that IL-10 has an unexpected negative effect on Aβ proteostasis and cognition in APP mouse models demonstrate the complex interplay between innate immunity and proteostasis in neurodegenerative diseases, an interaction we call immunoproteostasis.
|
25619653 |
2015 |
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The activity of beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is elevated during aging and in sporadic Alzheimer's disease (AD), but the underlying mechanisms of this change are not well understood. p25/Cyclin-dependent kinase 5 (Cdk5) has been implicated in the pathogenesis of several neurodegenerative diseases, including AD.
|
26317805 |
2015 |